1YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| Compstatin | COMPSTATIN | 206645-99-0 |
| AF12198 | AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2 | 185413-30-3 |
| Pam3CSK4 TFA | 化合物PAM3CSK4 TFA | 112208-01-2 |
| G3-C12 | G3-C12 | 848301-94-0 |
| AMY-101 TFA | AMY-101 TFA | 1789738-04-0 |
| Tat-NR2Baa | Tat-NR2Baa | 847829-41-8 |
| Human PD-L1 inhibitor II | HUMAN PD-L1 INHIBITOR II | 2135542-85-5 |
| Human PD-L1 inhibitor IV | HUMAN PD-1 PROTEIN抑制剂多肽 | 2135542-83-3 |
| Reslizumab | RESLIZUMAB | 241473-69-8 |
| Nitroflurbiprofen | 158836-71-6 | 158836-71-6 |
| SC57666 | 158959-32-1 | 158959-32-1 |
| FR-188582 | 189699-82-9 | 189699-82-9 |
| Pamicogrel | 101001-34-7 | 101001-34-7 |
| Nivolumab | 纳武单抗 | 946414-94-4 |
| Atezolizumab | 阿特珠单抗 | 1380723-44-3 |
| Ustekinumab | 乌司奴单抗 | 815610-63-0 |
| Durvalumab | 德瓦鲁单抗 | 1428935-60-7 |
| Benralizumab | BENRALIZUMAB | 1044511-01-4 |
| Dupilumab | 度匹鲁单抗 | 1190264-60-8 |
| Neoseptin 3 | 1622863-21-1 | 1622863-21-1 |
| Bropirimine | 溴匹立明 | 56741-95-8 |
| Phenethyl ferulate | 阿魏酸苯乙酯 | 71835-85-3 |
| Phenidone | 菲尼酮 | 92-43-3 |
| Citronellol | 香茅醇 | 106-22-9 |
| DL-Norvaline | DL-正缬氨酸 | 760-78-1 |
| NLRP3-IN-2 | 4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺 | 16673-34-0 |
| Benzyl butyl phthalate | 邻苯二甲酸丁苄酯 | 85-68-7 |
| Pelargonidin chloride | 氯化花葵素 | 134-04-3 |
| Cridanimod | 吖啶酮乙酸 | 38609-97-1 |
| 2,5-Di-tert-butylhydroquinone | 2,5-二特丁基对苯二酚 | 88-58-4 |
| D-Kynurenine | 犬尿氨酸 | 13441-51-5 |
| 3-Indolepropionic acid | 吲哚-3-丙酸 | 830-96-6 |
| Hydroxychloroquine | 羟基氯喹 | 118-42-3 |
| RO8191 | 8-(1,3,4-OXADIAZOL-2-YL)-2,4-BIS(TRIFLUOROMETHYL)IMIDAZO[1,2-A][1,8]NAPHTHYRIDINE | 691868-88-9 |
| Methyl Salicylate | 水杨酸甲酯 | 119-36-8 |
| Sodium dichloroacetate | 二氯乙酸钠 | 2156-56-1 |
| PD-161570 | PD-161570;PF-1480232 | 192705-80-9 |
| HO-3867 | HO-3867 | 1172133-28-6 |
| BP-1-102 | 4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 | 1334493-07-0 |
| SH5-07 | 1456632-41-9 | 1456632-41-9 |
| HJC0152 hydrochloride | 2-(2-氨基乙氧基)-5-氯-N-(2-氯-4-硝基苯基)苯甲酰胺盐酸盐 | 1420290-99-8 |
| STAT3-IN-1 | STAT3-IN-1 | 2059952-75-7 |
| PF-06651600 | 利特昔替尼 | 1792180-81-4 |
| TX1-85-1 | TX1-85-1 | 1603845-32-4 |
| PF-06263276 | PF-06263276 (PF 6263276) | 1421502-62-6 |
| TP-3654 | TP3654 | 1361951-15-6 |
| RG13022 | RG-13022 | 136831-48-6 |
| TyK2-IN-2 | 2098466-94-3 | 2098466-94-3 |
| STAT5-IN-1 | STAT5 Inhibitor | 285986-31-4 |
| INCB053914 phosphate | CS-2873 | 2088852-47-3 |
| SMI-16a | PIM1/2 KINASE INHIBITOR VI | 587852-28-6 |
| JAK3-IN-6 | JAK3-IN-6 | 1443235-95-7 |
| FM-381 | (E)-2-CYANO-3-(5-(1-CYCLOHEXYL-1,6-DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-2-YL)FURAN-2-YL)-N,N-DIMETHYLACRYLAMIDE | 2226521-65-7 |
| STAT5-IN-2 | STAT5-IN-2 | 2111834-61-6 |
| inS3-54A18 | 328998-53-4 | 328998-53-4 |
| RSVA405 | 化合物RSVA 405 | 140405-36-3 |
| BMS-690514 | (3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-F][1,2,4]三嗪-5-基]甲基]哌啶-3-醇 | 859853-30-8 |
| CGP52411 | CGP 52411 | 145915-58-8 |
| HKI-357 | HKI 357 | 848133-17-5 |
| AV-412 | AV 412 | 451493-31-5 |
| AV-412 free base | AV-412 | 451492-95-8 |
| Canertinib | 卡奈替尼 | 267243-28-7 |
| Pim1/AKK1-IN-1 | N-[5-(4-氰基苯基)-1H-吡咯并[2,3-B]吡啶-3-基]-3-吡啶甲酰胺 | 1093222-27-5 |
| Pyrotinib Racemate | 1246089-97-3 | 1246089-97-3 |
| Pyrotinib dimaleate | 马来酸吡咯替尼 | 1397922-61-0 |
| Theliatinib | 席栗替尼 | 1353644-70-8 |
| Fedratinib hydrochloride hydrate | TG-101348 | 1374744-69-0 |
| ARRY-380 (analog ) | ARRY-380 | 937265-83-3 |
| AZD4205 | AZD4205 | 2091134-68-6 |
| MTX-211 | MTX-211 | 1952236-05-3 |
| Epertinib hydrochloride | EPERTINIB HYDROCHLORIDE | 2071195-74-7 |
| Momelotinib sulfate | N-(氰基甲基)-4-[2-[[4-(4-吗啉基)苯基]氨基]-4-嘧啶基]苯甲酰胺硫酸盐(1:2) | 1056636-06-6 |
| (R)-Lisofylline | 1-(5-hydroxyhexyl)-3,7-dimethyl-purine-2,6-dione | 100324-81-0 |
| EGFR-IN-5 | EGFR-IN-5 | 2225887-26-1 |
| Tyk2-IN-5 | TYK2-IN-5 | 1797432-62-2 |
| TAS6417 | 齐帕勒替尼 | 1661854-97-2 |
| PD-089828 | PD089828 | 179343-17-0 |
| Protosappanin A | 原苏木素A | 102036-28-2 |
| G5-7 | 化合物JAK2 INHIBITOR G5-7 | 939681-36-4 |
| PKI-166 | PKI 166 | 187724-61-4 |
| Tyrphostin AG30 | 酪氨酸磷酸化抑制剂 AG 30 | 122520-79-0 |
| PF-06700841 P-Tosylate | CS-2860 | 2140301-96-6 |
| SHR0302 | 化合物SHR0302 | 1445987-21-2 |
| Almonertinib | 阿美替尼 | 1899921-05-1 |
| Almonertinib hydrochloride | HS-10296 HYDROCHLORIDE | 2134096-03-8 |
| JND3229 | JND3229 | 2260886-64-2 |
| RTC-5 | RTC-5 | 1423077-49-9 |
| CCT365623 hydrochloride | CCT365623 | 2126136-98-7 |
| SC99 | SC-99 | 882290-02-0 |
| JAK/HDAC-IN-1 | JAK/HDAC-IN-1 | 2284621-75-4 |
| Erlotinib D6 hydrochloride | 埃罗替尼-D6 盐酸盐 | 1189953-78-3 |
| BMS-599626 Hydrochloride | BMS-599626 | 873837-23-1 |
| UC-514321 | 化合物UC-514321 | 299420-83-0 |
| Gefitinib-based PROTAC 3 | Gefitinib-based PROTAC 3 | 2230821-27-7 |
| EGFR-IN-8 | EGFR-IN-8 | 2407957-87-1 |
| AS2863619 free base | AS2863619 free base | 2241300-50-3 |
| AS2863619 | AS2863619 | 2241300-51-4 |
| M-110 | CS-2124 | 1395048-49-3 |
| STAT3-IN-3 | STAT3-IN-3 | 2361304-26-7 |
| SI-109 | 2429877-30-3 |
联系方式
